3B BlackBio Dx Q1 FY27 results: Board meet Aug 13, 2026

Stock in focus ahead of results

3B BlackBio Dx Ltd (earlier Kilpest India Limited) is back on investor watchlists ahead of its June quarter earnings. As per the provided data, 3BBLACKBIO’s share price on 12 August 2026 was ₹1,251.10. Another price snapshot in the same context shows ₹1,244.00, up ₹35.15 or 2.91%.

The immediate trigger is the company’s scheduled board meeting to take up its first-quarter numbers for FY27. With FY26 now closed and audited, investors are looking for confirmation on whether the company’s growth momentum in molecular diagnostics continues into the new financial year.

Board meeting on August 13 for Q1 FY27 results

According to a regulatory filing with BSE Limited, the Board of Directors of 3B BlackBio Dx Limited will meet on Thursday, August 13, 2026, at 3:00 P.M. The primary agenda is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

The intimation does not disclose any specific financial figures for Q1 FY27. It only confirms that the financial results for the June 2026 quarter are pending board approval.

Trading window closure under insider trading rules

The company also reiterated its trading window restrictions under the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for the company’s equity shares for Designated Persons and their immediate relatives has been closed since July 1, 2026.

It will remain closed until 48 hours after the financial results are announced on August 13, 2026, with both days included. This is a standard compliance measure around unpublished price-sensitive information such as quarterly financial results.

FY26 audited performance: revenue about ₹142 crore, PAT near ₹60 crore

Management commentary and audited performance highlights in the provided material point to a strong FY26.

• Consolidated revenue for FY26 was approximately ₹142 crore.
• Profit After Tax (PAT) for FY26 was nearly ₹60 crore.

Another set of FY26 numbers provided in the text states that consolidated revenue from operations rose 47.1% to ₹141.92 crore (from ₹96.47 crore in FY25), while consolidated net profit increased 25.7% to ₹59.93 crore (from ₹47.69 crore in FY25). These figures align broadly with the “approximately ₹142 crore revenue” and “nearly ₹60 crore PAT” references.

The earnings call also attributed performance to a 10% growth in the molecular diagnostic business and contributions from TRUPCR Europe and Coris BioConcept.

Q4 FY26: higher revenue and EBITDA year-on-year

For the quarter ended March 31, 2026 (Q4 FY26), the company disclosed a sharp year-on-year rise in consolidated revenue and operating profit.

• Consolidated revenue: ₹35.43 crore in Q4 FY26 versus ₹22.50 crore in Q4 FY25 (up 57.52% YoY).
• Consolidated EBITDA: ₹18.64 crore in Q4 FY26 versus ₹12.86 crore in Q4 FY25 (up 44.93% YoY).
• Consolidated PAT: ₹9.80 crore in Q4 FY26 versus ₹8.04 crore in Q4 FY25 (up 22.02% YoY).

A separate disclosure in the text also mentions quarterly net profit of ₹9.56 crore for March 2026, compared with ₹8.40 crore in March 2025. The numbers are presented as reported in the supplied material and should be cross-checked with the exchange filing for the final audited tables.

Standalone Q4 snapshot and FY26 standalone totals

Alongside consolidated performance, the material includes standalone figures.

For Q4 FY26 on a standalone basis:

• Standalone revenue: ₹24.63 crore versus ₹23.02 crore YoY.
• Standalone net profit: ₹7.45 crore versus ₹9.24 crore YoY.

For the full year FY26 on a standalone basis:

• Standalone revenue from operations: ₹97.28 crore.
• Standalone net profit: ₹49.32 crore.

The board approved the audited standalone and consolidated financial results in its meeting held on May 29, 2026, and the statutory auditors issued an unmodified opinion, as stated in the provided text.

Dividend and other board decisions

For FY26, the Board recommended a final dividend of ₹5.00 per equity share, subject to shareholder approval at the ensuing Annual General Meeting. The provided material also notes the “current dividend yield” for 3B Blackbio DX Ltd (3BBLACKBIO) as 0.40.

The Board also appointed M/s Ali Jain & Sharma, Chartered Accountants, as the Internal Auditor for FY 2026-27.

Management outlook: FY27 revenue growth target

Management commentary cited in the material indicates confidence in sustaining growth into FY27. The company guided for revenue growth of 15% to 20%, potentially reaching ₹175 crore to ₹180 crore.

This outlook is framed in the context of the company’s FY26 base and the reported growth in its molecular diagnostic business. Investors will typically look for early signs of trajectory in Q1 FY27 numbers and any segment commentary provided with the results.

Market snapshot: price levels, market cap, and stated targets

The supplied text includes multiple market snapshots. One section quotes:

• CMP: ₹1,197
• Market capitalisation: ₹1,034 crore
• P/E: “Not meaningful”
• 12-month target range (Uniresearch estimate): ₹1,209 to ₹1,365

Separately, the text notes that the stock closed at ₹1,115.90 on June 2, 2026 (BSE) and delivered -10.48% returns over six months and -32.72% over the last 12 months.

Key facts table

Market Impact

The near-term market impact for 3B BlackBio Dx is primarily event-driven because the Q1 FY27 numbers are pending board approval and the company has not disclosed any Q1 financial figures in the intimation. Ahead of the announcement, investors are likely to anchor expectations to audited FY26 trends: revenue of about ₹142 crore and PAT near ₹60 crore, plus the sharp year-on-year rise in Q4 FY26 consolidated revenue to ₹35.43 crore.

The stock has been quoted at different points in the provided material, including ₹1,197 as CMP and ₹1,251.10 as of 12 August 2026, indicating elevated attention into the results window. Dividend expectations can also influence sentiment, with a stated dividend yield of 0.40 and a FY26 final dividend recommendation of ₹5 per share.

Analysis Section

Two data points stand out from the disclosed numbers. First, the FY26 jump in consolidated revenue from operations to ₹141.92 crore from ₹96.47 crore suggests a materially larger revenue base going into FY27. Second, Q4 FY26 shows operating leverage in consolidated EBITDA at ₹18.64 crore on revenue of ₹35.43 crore, alongside a consolidated PAT figure around ₹9.8 crore for the quarter.

Management’s FY27 revenue growth target of 15% to 20% (₹175 crore to ₹180 crore) provides a clear benchmark for investors to track. But since the Q1 FY27 result intimation contains no figures, the main analytical focus remains on verifying whether the June quarter performance stays consistent with the FY26 exit rate and whether the molecular diagnostics segment continues its reported 10% growth.

Conclusion

3B BlackBio Dx will consider and approve its unaudited Q1 FY27 standalone and consolidated results at a board meeting scheduled for August 13, 2026, at 3:00 P.M., with the trading window closed until 48 hours after the announcement. FY26 audited numbers indicate consolidated revenue of about ₹142 crore and PAT near ₹60 crore, and the company has outlined a FY27 revenue growth target of 15% to 20%. The next confirmed milestone is the board-approved Q1 FY27 financial release and related exchange filing.